Supreme Court rules stem cells as medicine
The Supreme Court has ruled that stem cells used to treat illnesses should be regarded as medicine that requires approval from the drug administration for use.
It also confirmed that hospitals should be held liable to compensate for damages inflicted upon patients due to stem cell transplantation, upholding a lower court’s decision.
Justice Min Young-il ruled in favor of 60-year-old Choi and eight others who filed a suit against Kim, an operator of a clinic in Seoul, because the stem cell transplantations they had received were not as effective as they were told they would be.
Min said, “Stem cell use is considered a medicine if it was extracted from the human body for treatment purposes. The clinic’s transplantation without approval from the Korea Food and Drug Administration is a violation of the Pharmaceuticals Law.
Moreover, the use of stem cells was still undergoing debate at the time and the practice was still in the experimental stage.”
He ordered the clinic to pay between 16 and 30 million won each to the nine plaintiffs for having failed to fully explain the risks associated with the practice and for providing uncertain information about the much-hyped treatment.
Choi, who suffers from hepatocirrhosis, read newspaper articles about Kim’s clinic’s having succeeded in treating the same disease for two patients with stem cells separated from cord blood in 2003.
Choi and eight others paid 20 million to 30 million won each and received transplantations but found no improvement. One of them even died soon afterwards.
Though the court penalized the clinic it restricted the hospital’s liability to 60-70 percent because Choi and the other patients were informed about the risk of the practice to a certain extent but insisted on receiving it anyway.
The plaintiffs had demanded the hospital pay 40 million to 50 million won in compensation.